AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PCVX · NASDAQ · Biotechnology

Vaxcyte

Developer of high-valency bacterial vaccine candidates using cell-free protein synthesis.

$59.50

After-hours close−0.31 (−0.52%)

At close$59.81(−2.20%)

Something off on this page? Send us feedback.

Profile

Vaxcyte, Inc.PCVXHealth Care

Develops high-valency bacterial vaccines using cell-free protein synthesis and site-specific conjugation, with pneumococcal candidates VAX-31, VAX-24, and VAX-XL at the center and earlier programs for Group A Strep and Shigella. With no approved products, funding supports trials and manufacturing scale-up rather than commercial sales.

Develops bacterial vaccines around a pneumococcal conjugate franchise led by VAX-31, now in late-stage adult trials and an infant study. VAX-24 has completed adult and infant mid-stage studies, while VAX-XL is a preclinical candidate for broader serotype coverage.

Pairs a licensed cell-free protein-synthesis system with carrier-sparing, site-specific conjugation to build high-valency vaccines. Beyond pneumococcus, VAX-A1 is in an early-stage adult study for Group A Strep, while VAX-GI for Shigella remains paused before further development.

Operates as a clinical-stage biotech with no approved products or product-sales revenue. Progress depends on clinical and regulatory outcomes, scaling a complex manufacturing process, continued financing, and contract partners for production and fill-finish.

Company facts

CEOGrant E. Pickering

ListedJun 12, 2020

ExchangeNASDAQ

HeadquartersSan Carlos, CA

CountryUnited States

Employees507

CIK0001649094

ISINUS92243G1085

Key statistics

Market cap$8.64B

EPS (ttm)−$7.64

P/E (ttm)−7.83

ROE-37.6%

P/B3.13

P/S0.00

Dividend yield—

Beta0.93vs XLV 0.96

Year to date +28.7% · Average volume (30d) 935.0K

Analysts

Price target, next 12 months$89.00+48.7%Median of 11 analysts · vs the Aug 28 close

ConsensusBuy11 of 11 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $59.84

High$163.00+172.4%

Median$89.00+48.7%

Low$58.00−3.1%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior target	Target
Feb 25, 2026	BTIG	Target	$160	$89
Nov 19, 2025	Leerink Partners	Target	$135	$77

Earnings

EPS

Estimate−$2.12

ReportedDue Nov 3, 2026

Revenue

Estimate$12.5M

ReportedDue Nov 3, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$2.06	−$1.97	+4.4%	$12.5M	—	—	+5.31%
May 6, 2026Q1 FY26	−$1.77	−$2.30	−29.7%	$12.5M	—	—	−9.84%
Feb 24, 2026Q4 FY25	−$1.53	−$1.80	−17.7%	$18.8M	—	—	+2.75%
Nov 4, 2025Q3 FY25	−$1.27	−$1.56	−22.8%	—	—	—	−2.49%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	−$5.0M	$0	$5.0M	−$5.9M	$0
Operating income	−$180.8M	−$226.2M	−$242.4M	−$274.3M	−$345.9M	−$302.8M
Net income	−$140.7M	−$166.6M	−$212.8M	−$246.5M	−$320.6M	−$284.3M
Diluted EPS	−$1.04	−$1.22	−$1.56	−$1.81	−$2.30	−$1.97
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $1.49B · Total debt $115.4M · Total assets $3.14B · Shareholders' equity $2.76B

Dividends

No dividends on record.

Ownership

Institutions 122.27%Insiders 0.79%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 144.40M · Float 132.08M · 91.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
FMR LLC	20.85M	14.44%	13F	Aug 13, 2026
Jupiter Topco LLC	17.97M	12.44%	13F	Aug 14, 2026
Janus Henderson Group PLC	16.58M	11.50%	13G	May 15, 2026
T. Rowe Price Investment Management, Inc.	12.21M	8.45%	13F	Aug 14, 2026
BlackRock, Inc.	12.07M	8.36%	13F	Aug 7, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 3, 2026	Andrew Guggenhime	officer: PRESIDENT AND CFO	−10,000	$53.89
Aug 3, 2026	Jim Wassil	officer: CHIEF OPERATING OFFICER	−2,250	$53.86
Aug 5, 2026	Harpreet S. Dhaliwal	officer: Chief Technical Ops Officer	−17,000	$55.00
Jul 27, 2026	Grant Pickering	director, officer: CHIEF EXECUTIVE OFFICER	−18,198	$55.63
Jul 1, 2026	Jim Wassil	officer: CHIEF OPERATING OFFICER	−2,250	$56.33